Page 26 of 31: studies 251 to 260 of 308, newest first. Back to the psilocybin for anxiety overview
Carolina Digital Repository August 7, 2020 John D. Mccorvy, R.h.j. Olsen, B.l. Roth
[No abstract available]
August 5, 2020 Sofia Beck 1 citation
Depression and anxiety are debilitating mental health conditions that affect a large portion of the United States. Current pharmacological treatments for these disorders require daily administration, are associated with a number of side effects, and can be ineffective for some. Emerging evidence in novel treatment options may necessitate a shift toward how we treat these psychiatric disorders.
Journal of Psychoactive Drugs June 12, 2020 Jason B. Luoma, Christina Chwyl, Geoff J. Bathje et al. 206 citations
After a two-decade hiatus in which research on psychedelics was essentially halted, placebo-controlled clinical trials of psychedelic-assisted therapy for mental health conditions have begun to be published. We identified nine randomized, placebo-controlled clinical trials of psychedelic-assisted therapy published since 1994. Studies examined psilocybin, LSD (lysergic acid diethylamide),...
Proceedings of the National Academy of Sciences April 13, 2020 Morten L. Kringelbach, Josephine Cruzat, Joana Cabral et al. 326 citations
Significance In a technical tour de force, we have created a framework demonstrating the underlying fundamental principles of bidirectional coupling of neuronal and neurotransmitter dynamical systems. Specifically, in the present study, we combined multimodal neuroimaging data to causally explain the functional effects of specific serotoninergic receptor (5-HT 2A R) stimulation with psilocybin...
Molecules March 5, 2020 J Benko, Stanislava Vranková 18 citations
Increasing prevalence and burden of major depressive disorder presents an unavoidable problem for psychiatry. Existing antidepressants exert their effect only after several weeks of continuous treatment. In addition, their serious side effects and ineffectiveness in one-third of patients call for urgent action. Recent advances have given rise to the concept of psychoplastogens. These compounds...
ACS Chemical Neuroscience March 5, 2020 Meghan Hibicke, Alexus N. Landry, Hannah M. Kramer et al. 211 citations
Psilocybin shows efficacy to alleviate depression in human clinical trials for six or more months after only one or two treatments. Another hallucinogenic drug, esketamine, has recently been U.S. Food and Drug Administration (FDA)-approved as a rapid-acting antidepressant. The mechanistic basis for the antidepressant effects of psilocybin and ketamine appear to be conserved. The efficacy of...
March 1, 2020 Adam Winstock, James W. Rucker 29 citations
Abstract Psychedelics and hallucinogens represent some of the most commonly used drugs in the world, with a history of use steeped in spirituality, counter-culture, and more recently latent therapeutic potential. Sharing a common mechanism of action at the 5-HT2a receptor, drugs such as lysergic acid diethylamide (LSD) and psilocybin, while they can rarely induce significant short-term...
Journal of Psychopharmacology February 28, 2020 Daniel Rosenbaum, Cory R. Weissman, Thomas Anderson et al. 75 citations
Rationale: Microdosing psychedelics – the practice of consuming small, sub-hallucinogenic doses of substances such as LSD or psilocybin – is gaining attention in popular media but remains poorly characterized. Contemporary studies of psychedelic microdosing have yet to report the basic psychiatric descriptors of psychedelic microdosers. Objectives: To examine the practices and demographics of a...
Scientific Reports February 10, 2020 Frederick S. Barrett, Manoj K. Doss, Nathan D. Sepeda et al. 375 citations
Psilocybin is a classic psychedelic compound that may have efficacy for the treatment of mood and substance use disorders. Acute psilocybin effects include reduced negative mood, increased positive mood, and reduced amygdala response to negative affective stimuli. However, no study has investigated the long-term, enduring impact of psilocybin on negative affect and associated brain function....
Journal of the Neurological Sciences January 31, 2020 Tingying Chi, Jessica A. Gold 95 citations
Though there was initial interest in the use of psychedelic drugs for psychiatric treatment, bad outcomes and subsequent passage of the Substance Act of 1970, which placed psychedelic drugs in the Schedule I category, significantly limited potential progress. More recently, however, there has been renewal in interest and promise of psychedelic research. The purpose of this review is to...